Regadenoson
- Generic Name
- Regadenoson
- Brand Names
- Lexiscan, Rapiscan
- Drug Type
- Small Molecule
- Chemical Formula
- C15H18N8O5
- CAS Number
- 313348-27-5
- Unique Ingredient Identifier
- 7AXV542LZ4
- Background
Regadenoson is an A2A adenosine receptor agonist that causes coronary vasodilation and used for myocardial perfusion imagining. Manufactured by Astellas and FDA approved April 10, 2008.
- Indication
Diagnostic agent for radionuclide myocardial perfusion imaging (MPI)
- Associated Conditions
- -
- Associated Therapies
- -
ADVANCE MPI 1: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2009-11-26
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 1231
- Registration Number
- NCT00208299
- Locations
- 🇺🇸
Multiple study locations (see Central Contact); CV Therapeutics, Inc., Palo Alto, California, United States
ADVANCE MPI 2: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2009-11-26
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 787
- Registration Number
- NCT00208312
- Locations
- 🇺🇸
Multiple study locations (see Central Contact); CV Therapeutics, Inc., Palo Alto, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath